Haleon plc ADRHLN
Price$8.72Intrinsic value$13.5656% above price

Qualitative Analysis

Business overview

Business Overview

Haleon plc is one of the world's largest standalone consumer healthcare companies, established in July 2022 following its corporate spin-off from GlaxoSmithKline (GSK) and the integration of consumer health portfolios from GSK, Pfizer, and Novartis. Headquartered in Weybridge, United Kingdom, the company operates across more than 170 markets globally. Haleon's extensive product portfolio is organized into six major categories: Oral Health (featuring Sensodyne, parodontax, and Polident), Vitamins, Minerals and Supplements (Centrum, Emergen-C, Caltrate), Pain Relief (Advil, Panadol, Voltaren), Respiratory Health (Theraflu, Flonase, Otrivin), Digestive Health (TUMS, ENO), and Therapeutic Skin Health. The company's business model leverages trusted science, clinical substantiation, and strong recommendations from healthcare professionals to drive premium positioning and recurring consumer usage.

Research as of 29 Jul 2026

Strategic Initiatives

Growth programs, investments, and their expected impact

AI-assisted
Win as One StrategyTransformation

A comprehensive strategic plan focused on three core priorities: delivering consistent growth, unlocking productivity gains, and embedding an agile, performance-focused culture.

Expected impact: Aims to reach one billion more consumers by 2030 and deliver industry-leading shareholder returns.

Sign in / Sign up to read more
InvestmentSupported by the reallocation of resources and productivity savings.
TimelineLaunched in May 2025 with ongoing execution through 2030.
Operating Model EvolutionEfficiency

Streamlining the organizational structure by creating a new Chief Growth Officer (CGO) role and establishing six distinct Operating Units (OUs) to bring the voice of consumers deeper into strategic decision-making.

Expected impact: Expected to deliver annualized gross cost savings of £175 million to £200 million over the next two years, leveraging automation, AI, and a streamlined category-led structure.

Sign in / Sign up to read more
InvestmentRestructuring costs integrated into the general productivity program.
TimelineAnnounced in January 2026, with implementation targeted by mid-2026.
Supply Chain Productivity ProgramEfficiency

Optimizing the global supply chain by reducing SKUs, packaging, and formulations by approximately 30%, and increasing multi-sourcing of ingredients to around 90%.

Expected impact: Aims to unlock £800 million in gross supply chain savings over five years, driving 50 to 80 basis points of adjusted gross profit margin expansion per annum.

Sign in / Sign up to read more
InvestmentPhased capital expenditure, including new facilities in China and India.
TimelineFive-year program running through 2030.
Health Inclusivity and Sustainability StrategyTransformation

A global initiative to boost health literacy, increase access to everyday healthcare products in underserved communities, and reduce environmental impact.

Expected impact: Aims to provide opportunities for over 300 million people a year to take more control of their everyday health by 2030, building on the previous goal of empowering 50 million people.

Sign in / Sign up to read more
InvestmentFunded through corporate social responsibility and operational ESG budgets.
TimelineTargeting key goals by 2030.
Sources: 4

Mergers, Acquisitions & Partnerships

Recent deals and strategic collaborations

AI-assisted

Strategic Partnerships

CARE InternationalSocial Impact & Health Literacy Partnership

Supports Haleon's Better Everyday Health Project to equip community health workers with practical tools and training, boosting health literacy and access to products in underserved communities.

Terms: Terms of the funding and product donations are not publicly disclosed.

Sign in / Sign up to read more
Sources: 1
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.